A single centre cohort experience with a new once daily antiretroviral drug | Zendy

Justin Stebbing | Zendy; Mark Bower | Zendy; Paul Holmes | Zendy; Brian Gazzard | Zendy; Mark Nelson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A single centre cohort experience with a new once daily antiretroviral drug

Author(s) -

Justin Stebbing,

Mark Bower,

Paul Holmes,

Brian Gazzard,

Mark Nelson

Publication year - 2006

Publication title -

postgraduate medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.568

H-Index - 99

eISSN - 1469-0756

pISSN - 0032-5473

DOI - 10.1136/pgmj.2006.044867

Subject(s) - atazanavir , medicine , cohort , dosing , protease inhibitor (pharmacology) , viral load , cohort study , antiretroviral therapy , human immunodeficiency virus (hiv) , ritonavir , immunology

Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is also used in highly active antiretroviral therapy (HAART) naive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research